The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease.

ABSTRACT:

Background

Although major guidelines uniformly recommend iron supplementation and erythropoietin stimulating agents (ESAs) for managing chronic anemia in persons with chronic kidney disease (CKD), there are differences in the recommended hemoglobin (Hb) treatment target and no guidelines consider the costs or cost-effectiveness of treatment. In this study, we explored the most cost-effective Hb target for anemia treatment in persons with CKD stages 3-4.

Methods and findings

The CKD Health Policy Model was populated with a synthetic cohort of persons over age 30 with prevalent CKD stages 3-4 (i.e., not on dialysis) and anemia created from the 1999-2010 National Health and Nutrition Examination Survey. Incremental cost-effectiveness ratios (ICERs), computed as incremental cost

SUBMITTER: Yarnoff BO 

PROVIDER: S-EPMC4942058 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature